Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Non-Current Assets (2018 - 2023)

Historic Non-Current Assets for Marker Therapeutics (MRKR) over the last 6 years, with Q1 2023 value amounting to $17.0 million.

  • Marker Therapeutics' Non-Current Assets fell 2886.74% to $17.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $17.0 million, marking a year-over-year decrease of 2886.74%. This contributed to the annual value of $17.8 million for FY2022, which is 1963.62% down from last year.
  • Per Marker Therapeutics' latest filing, its Non-Current Assets stood at $17.0 million for Q1 2023, which was down 2886.74% from $17.8 million recorded in Q4 2022.
  • Over the past 5 years, Marker Therapeutics' Non-Current Assets peaked at $23.9 million during Q1 2022, and registered a low of $872702.0 during Q4 2019.
  • Its 5-year average for Non-Current Assets is $14.3 million, with a median of $18.2 million in 2020.
  • In the last 5 years, Marker Therapeutics' Non-Current Assets skyrocketed by 232968.96% in 2020 and then plummeted by 2886.74% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Non-Current Assets stood at $872702.0 in 2019, then soared by 2329.69% to $21.2 million in 2020, then rose by 4.48% to $22.2 million in 2021, then fell by 19.64% to $17.8 million in 2022, then decreased by 4.35% to $17.0 million in 2023.
  • Its last three reported values are $17.0 million in Q1 2023, $17.8 million for Q4 2022, and $18.7 million during Q3 2022.